Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progress in active-specific immunotherapy of brain malignancies.

B A Tjoa1, M L Salgaller

  • 1Northwest Biotherapeutics, Inc., 21710 23rd Drive SE, Suite 100, Bothell, WA 98021, USA. mls@nwbio.org

Expert Opinion on Investigational Drugs
|November 4, 2000
PubMed
Summary

Cancer vaccines, or active-specific immunotherapy, offer a promising approach for treating malignant brain tumors. Dendritic cell-based vaccines show encouraging preclinical results for brain cancer, with high hopes for clinical translation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AACR - 91st meeting. Dendritic cell vaccine strategies.

IDrugs : the investigational drugs journal·2005
Same author

AACR - 91st meeting. Satellite meeting - immunotherapy of cancer.

IDrugs : the investigational drugs journal·2005
Same author

Immunosuppressive factors in the tumor environment: Potential implications for immune-based therapies.

IDrugs : the investigational drugs journal·2005
Same author

92nd AACR. Immunotherapy of cancer.

IDrugs : the investigational drugs journal·2005
Same author

Therapeutic potential of dendritic-based vaccines.

Expert opinion on investigational drugs·2005
Same author

Advances in oncology--clinical advances and molecular oncology.

IDrugs : the investigational drugs journal·2005

Area of Science:

  • Neuro-oncology
  • Immunotherapy
  • Vaccinology

Background:

  • Malignant brain tumors have a poor prognosis despite advances in surgery and oncology.
  • Current treatment options for brain malignancies have limited efficacy.
  • Immunotherapeutic approaches, particularly cancer vaccines, are being investigated as novel treatment strategies.

Purpose of the Study:

  • This review summarizes the development of cancer vaccines for malignant brain tumors.
  • It explores the mechanisms of vaccine-induced immune responses.
  • The review highlights the potential of dendritic cell-based vaccines in neuro-oncology.

Main Methods:

  • Review of preclinical and clinical studies on cancer vaccines for brain malignancies.
  • Analysis of immune response mechanisms initiated by vaccinations.

Related Experiment Videos

  • Focus on dendritic cell-based vaccine strategies.

    • Main Results:

    • Understanding immune responses has improved vaccine design and efficacy.
    • Dendritic cell-based vaccines represent a new generation of cancer vaccines.
    • Preclinical data for dendritic cell vaccines in malignant brain tumors are promising.

    Conclusions:

    • Active-specific immunotherapy, including cancer vaccines, holds promise for brain tumor treatment.
    • Dendritic cell-based vaccines are a significant advancement in this field.
    • Clinical application of these vaccines is anticipated with optimism.